Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study.

Mil Med Res · 2025 · PMC12477784 · PMID 41024116

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendP = 0.075so close (0.05 < p ≤ 0.1)

In the sensitivity analysis, xenopax showed a trend toward a better ORR at any time compared with BATs [82.6% (95% CI 76.9–88.3%) vs. 76.3% (95% CI 74.3–79.2%), P = 0.075], and the ORR at day 28 [64.5% (95% CI 57.3–71.7%) vs. 67.9% (95% CI 64.7–71.1%), P = 0.399] was similar between the groups in the propensity score matching (PSM) analysis.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.